Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Genequantum Healthcare (Suzhou) Co. Ltd. is managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units and 3 distinct examiners. PUTTLITZ, KARL J is the busiest examiner for the company, currently handling 2 pending actions. This concentration means that half of the company's current pending actions are under the review of a single examiner, making their specific examination style a critical factor for the portfolio.
The remaining 2 pending office actions are split among the other 2 distinct examiners. With 3 distinct art units involved, the company's pharmaceutical portfolio shows some technical diversity, though the prosecution is relatively concentrated with PUTTLITZ, KARL J. Practitioners should focus on this examiner's specific requirements, as their decisions will impact 2 of the 4 active cases. The involvement of 3 distinct examiners across 3 distinct art units suggests that while there is some concentration, the company still faces a variety of perspectives within the Biotechnology & Pharmaceuticals field. Successfully resolving the 4 pending office actions will require balancing the focused strategy needed for PUTTLITZ, KARL J with the broader requirements of the other examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PUTTLITZ, KARL J | 2 | 69.2% | +18.5% |
| EVANS, JASMINE AFIYA | 1 | 100.0% | +0.0% |
| NGUYEN, TAM M | 1 | 77.1% | +11.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18851893 | A FREEZE-DRYING PROCESS FOR AN ADC | EVANS, JASMINE AFIYA | — |
| 18410200 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18001764 | NOVEL ISOMERIC COMPOUNDS COMPRISING A RING-OPENED THIOSUCCINIMIDE GROUP, AN OLIGOPEPTIDE FRAGMENT AND A CHIRAL MOIETY | NGUYEN, TAM M | 25d overdue |
| 18410200 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | — |
| 18408826 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | — |
| Art Unit | Apps |
|---|---|
| 1646 | 2 |
| 1616 | 1 |
| 1771 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18851893 | A FREEZE-DRYING PROCESS FOR AN ADC | EVANS, JASMINE AFIYA | 1616 | §103§112 | Non-Final OA | — | Pending | Sep 27, 2024 |
| 18410200 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | 1646 | §102§103§112 | Non-Final OA | — | Pending | Jan 11, 2024 |
| 18408826 | STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | PUTTLITZ, KARL J | 1646 | §103§112DP | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18001764 | NOVEL ISOMERIC COMPOUNDS COMPRISING A RING-OPENED THIOSUCCINIMIDE GROUP, AN OLIGOPEPTIDE FRAGMENT AND A CHIRAL MOIETY | NGUYEN, TAM M | 1771 | §103 | Final Rejection | 25d overdue | Pending | Dec 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGenequantum Healthcare (Suzhou) Co. Ltd. has 4 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Karl J Puttlitz has the most, with 2 of Genequantum Healthcare (Suzhou) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
